CELLTRION, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 176,600 KRW | -0.45% |
|
+2.14% | -12.36% |
| Apr. 24 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
| Apr. 17 | Celltrion, Inc. announces an Equity Buyback for 436,047 shares. | CI |
ETFs positioned on Celltrion, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.14% | 2 M€ | -14.14% | ||
| 0.99% | 11 M€ | -.--% | - | |
| 0.53% | 15 M€ | +11.24% | ||
| 0.18% | 2,808 M€ | +5.90% | - | |
| 0.18% | 149 M€ | +2.17% | - | |
| 0.18% | 441 M€ | +4.60% | - | |
| 0.15% | 4 M€ | -4.41% | - | |
| 0.06% | 11 M€ | +1.79% | ||
| 0.05% | 7 M€ | +1.95% | - | |
| 0.05% | 117 M€ | +1.11% | - | |
| 0.04% | 1 M€ | +3.49% | - | |
| 0.04% | 3 M€ | -.--% | - | |
| 0.04% | 0 M€ | 0.00% | - | |
| 0.02% | 34 M€ | +6.71% | - | |
| 0.02% | 302 M€ | +3.80% | - | |
| 0.02% | 39 M€ | +3.67% | - | |
| 0.02% | 389 M€ | +6.83% | - | |
| 0.01% | 108 M€ | +2.03% | - | |
| 0.01% | 17 M€ | +1.44% | - | |
| 0.01% | 147 M€ | +4.88% | - | |
| 0.01% | 52 M€ | -0.60% | - | |
| 0.01% | 8 M€ | -0.60% | - |
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
176,600
KRW
Average target price
227,765
KRW
Spread / Average Target
+28.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.36% | 26.59B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B | |
| -16.98% | 10.07B |
- Stock Market
- Equities
- A068270 Stock
- Funds and ETFs Celltrion, Inc.
